Elevance Health (ELV) Expected to Release Quarterly Earnings on Wednesday

Elevance Health (NYSE:ELV) is anticipated to announce its Q2 2026 results before the market opens on Wednesday, July 15th. Analysts expect Elevance Health to announce earnings of $6.18 per share and revenue of $48.8170 billion for the quarter. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 15, 2026 at 8:30 AM ET.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.97 EPS. On average, analysts expect Elevance Health to post $27 EPS for the current fiscal year and $29 EPS for the next fiscal year.

Elevance Health Stock Down 0.7%

Elevance Health stock opened at $415.99 on Thursday. Elevance Health has a 52 week low of $273.71 and a 52 week high of $427.19. The stock has a market cap of $90.34 billion, a price-to-earnings ratio of 17.69, a PEG ratio of 2.38 and a beta of 0.67. The company’s 50-day moving average price is $395.21 and its two-hundred day moving average price is $352.48. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were issued a $1.72 dividend. The ex-dividend date was Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Truist Financial increased their price target on Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Sanford C. Bernstein boosted their price target on shares of Elevance Health from $424.00 to $482.00 and gave the company an “outperform” rating in a report on Thursday, July 2nd. Mizuho increased their price objective on Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Barclays lifted their target price on shares of Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Finally, Guggenheim boosted their price target on Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Fifteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and an average price target of $422.10.

Insider Transactions at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Elevance Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pettinga Financial Advisors LLC raised its holdings in Elevance Health by 4.8% in the 4th quarter. Pettinga Financial Advisors LLC now owns 812 shares of the company’s stock valued at $285,000 after acquiring an additional 37 shares in the last quarter. Foresight Global Investors Inc. grew its holdings in shares of Elevance Health by 5.6% during the 4th quarter. Foresight Global Investors Inc. now owns 865 shares of the company’s stock worth $303,000 after purchasing an additional 46 shares in the last quarter. UMB Bank n.a. increased its position in shares of Elevance Health by 2.6% during the fourth quarter. UMB Bank n.a. now owns 2,113 shares of the company’s stock valued at $741,000 after purchasing an additional 53 shares during the period. HM Payson & Co. increased its position in shares of Elevance Health by 15.0% during the fourth quarter. HM Payson & Co. now owns 437 shares of the company’s stock valued at $153,000 after purchasing an additional 57 shares during the period. Finally, CreativeOne Wealth LLC raised its stake in shares of Elevance Health by 4.4% in the third quarter. CreativeOne Wealth LLC now owns 1,569 shares of the company’s stock valued at $507,000 after purchasing an additional 66 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.